Forward P/S Multiple: Carlsmed (CARL)

Carlsmed Inc - graphic logo of issuer CARL

The investment potential of Carlsmed Inc (CARL) is driven by Cheryl Blanchard's expertise in developing breakthrough surgical solutions. The forward P/S ratio on the GURU.Markets chart illustrates the valuation trend, where the metric stands at 6.50. Strict FDA requirements and unique patents for AI implants serve as the foundation. Focused management and the confidence of major institutional investors in the secure software ensure price stability.

carlsmed.com - CARL Market Cap to Projected Revenue (period 07/24/2025 - 11/16/2026)

Summary analytical data breakdowns for Carlsmed Inc (CARL)

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Fundamental company analysis:CARL (Carlsmed Corp)
Product sample of Carlsmed Medical

To minimize the risk of asset undervaluation, it is essential to correlate market value with expected revenue, which is critical for Carlsmed Inc. (CARL) and its high-margin JIT delivery model for customized implants. By analyzing the forward P/S trend, an investor determines the value of each projected dollar of sales, assessing how effectively the market prices in the future expansion of digital manufacturing and the operational resilience of the business.

Who Carlsmed Inc competes with

Forward P/S Multiple BSX (bostonscientific.com)|EW: Market Cap to Projected Revenue|ResMed - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Corporation|ZBH: Forward P/S Multiple|COO - Market Cap to Expected Sales Ratio|ALGN (Align Corp) - Forward P/S Multiple|Globus Medical Corp (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Holdings, Inc. ATEC|Forward P/S Multiple AORT (artivion.com)|Forward P/S Multiple Enovis Corp ENOV|IART - Price-to-Projected Revenue Ratio|ESTA: Price-to-Projected Revenue Ratio|BBNX (Beta Bionics Inc) - Forward Price-to-Revenue Multiple|IRADIMED CORPORATION - Forward Price to Sales|EMBC (Embecta Health) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Tandem Diabetes Care Inc TNDM|Price-to-Projected Revenue Ratio AxoGen Inc (AXGN)|SI-BONE, Inc. (SIBN) - Projected Price to Revenue|Orthofix Corp - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio bioventus.com (BVS)|OrthoPediatrics Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Treace Medical Concepts Inc TMCI|Strata Critical Medical (SRTA) - Price-to-Projected Revenue Ratio|Future Price to Revenue RXST (RxSight Ophthalmic)|Price-to-Projected Revenue Ratio clearpointneuro.com|Forward Price-to-Revenue Multiple Stereotaxis, Inc. (STXS)|Forward P/S Multiple STIM|SGHT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Orchestra BioMed, Inc. OBIO|ANIK: Market Cap to Projected Revenue|NSPR: Forward Price-to-Revenue Multiple|Jin Medical - Price to Expected Revenue Ratio|VANI (Vivani Medical Inc) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue XTNT|NMTC (n1mtc.com) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Modular Medical MODD|Price-to-Projected Revenue Ratio myomo.com (MYO)|Price-to-Projected Revenue Ratio COCH (envoymedical.com)|Price-to-Projected Revenue Ratio Vivos Therapeutics Inc VVOS|enVVeno Medical Corp. - Price-to-Projected Revenue Ratio|SINT: Forward Price-to-Revenue Multiple|TNON (Tenon Medical, Inc.) - Market Cap to Projected Revenue|Lifeward Ltd. (LFWD) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Autonomix (AMIX)|Price-to-Projected Revenue Ratio INVO Fertility|Bone Biologics Corp. (BBLG) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple AXNX (Axonics Modulation Technologies)|BIOL (Biolase, Inc.) - Forward Price to Sales|Forward P/S Multiple DYNT (dynatronics.com)|Forward Price to Sales FNA|INVO Bioscience - Forward P/S Multiple